Lek Pharmaceuticals Inc.
!S!WCRTESTINPUT000000!E!
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Lek Pharmaceuticals Inc.
Vincerx Blames Stock Plunge On Overheated ADC Expectations
Expectations of robust efficacy from Phase I studies may be unrealistic, but spooked investors have made Vincerz’s cash flow problems even more acute.
Stock Watch: Pharma Businesses That Leave Consumer Behind
Healthcare conglomerates that divorce consumer, animal health and even generics businesses from their pure-play branded pharmaceutical groups could leave a less diversified and riskier sector in uncertain times. But the advantages are apparent.
Sellas Teases Biomarker-Driven Efficacy Of AML Drug With Phase IIa Results
The company remained tight-lipped on the biomarker driving high response rates for its CDK9 inhibitor SLS009 from a Phase II trial, as a Phase III interim analysis for its AML cancer vaccine galinpepimut-S draws near.
Masimo’s MightySat Receives First FDA Clearance For OTC Pulse Oximeter
The first clearance from the US Food and Drug Administration for an over-the-counter fingertip pulse oximeter has gone to Masimo's MightySat Medical, which is now available at the company's website.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice